Subtopic Deep Dive

CRISPR-Cas9 Genome Editing Delivery
Research Guide

What is CRISPR-Cas9 Genome Editing Delivery?

CRISPR-Cas9 genome editing delivery uses viral and non-viral vectors to transport Cas9 protein and guide RNA into cells for precise DNA cleavage and repair.

Delivery methods include lipid nanoparticles, exosomes, and ribonucleoproteins (RNPs) to enhance editing efficiency while reducing off-target effects. Key advances feature selective organ targeting (SORT) nanoparticles for tissue-specific CRISPR-Cas9 editing (Cheng et al., 2020). Over 10 high-citation papers from 2014-2021 detail RNP delivery and nanoparticle optimizations, with foundational work on purified Cas9 RNPs achieving high human cell editing rates (Kim et al., 2014).

15
Curated Papers
3
Key Challenges

Why It Matters

Efficient CRISPR-Cas9 delivery enables gene therapy for genetic disorders like HIV latency, as shown by RNA-directed editing eradicating latent HIV-1 (Hu et al., 2014). SORT nanoparticles achieve tissue-specific mRNA and CRISPR editing, expanding therapeutic applications (Cheng et al., 2020). Lipid nanoparticles improve mRNA delivery for Cas9 expression, supporting clinical translation (Hou et al., 2021). These methods minimize immune responses and off-target cuts, critical for in vivo treatments (Kim et al., 2014).

Key Research Challenges

Off-target editing minimization

Cas9 RNPs cause unintended DNA cuts despite high on-target efficiency in human cells (Kim et al., 2014). Optimizing guide RNA and delivery timing reduces off-targets but requires vector-specific tuning. Exosomes offer natural shielding yet face cargo loading inconsistencies (Pegtel and Gould, 2019).

Tissue-specific delivery

Achieving organ-selective CRISPR editing demands nanoparticles like SORT systems (Cheng et al., 2020). Viral vectors risk immunogenicity, while non-viral options struggle with endosomal escape. Balancing efficiency and specificity remains key for in vivo applications.

In vivo efficiency scaling

RNP delivery via cell-penetrating peptides disrupts genes effectively in vitro but scales poorly in animals (Ramakrishna et al., 2014). Lipid nanoparticles enhance mRNA-Cas9 expression yet face stability challenges in circulation (Hou et al., 2021). Sustained editing without toxicity hinders therapeutic progress.

Essential Papers

1.

Engineering precision nanoparticles for drug delivery

Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley et al. · 2020 · Nature Reviews Drug Discovery · 6.7K citations

2.

Lipid nanoparticles for mRNA delivery

Xucheng Hou, Tal Zaks, Róbert Langer et al. · 2021 · Nature Reviews Materials · 3.1K citations

3.

Exosomes

D. Michiel Pegtel, Stephen J. Gould · 2019 · Annual Review of Biochemistry · 2.6K citations

Exosomes are small, single-membrane, secreted organelles of ∼30 to ∼200 nm in diameter that have the same topology as the cell and are enriched in selected proteins, lipids, nucleic acids, and glyc...

4.

mRNA-based therapeutics — developing a new class of drugs

Uğur Şahin, Katalin Karikó, Özlem Türeci · 2014 · Nature Reviews Drug Discovery · 2.3K citations

5.

Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing

Qiang Cheng, Tuo Wei, Lukas Farbiak et al. · 2020 · Nature Nanotechnology · 2.0K citations

6.

Advances in oligonucleotide drug delivery

Thomas C. Roberts, Róbert Langer, Matthew J. A. Wood · 2020 · Nature Reviews Drug Discovery · 1.8K citations

7.

Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins

Sojung Kim, Daesik Kim, Seung Woo Cho et al. · 2014 · Genome Research · 1.8K citations

RNA-guided engineered nucleases (RGENs) derived from the prokaryotic adaptive immune system known as CRISPR (clustered, regularly interspaced, short palindromic repeat)/Cas (CRISPR-associated) enab...

Reading Guide

Foundational Papers

Start with Kim et al. (2014) for RNP delivery benchmarks in human cells, then Ramakrishna et al. (2014) on peptide-mediated Cas9 transport, as they establish core non-viral methods.

Recent Advances

Study Cheng et al. (2020) for SORT nanoparticles enabling organ-specific editing, and Hou et al. (2021) for LNP-mRNA Cas9 advances.

Core Methods

Core techniques: purified Cas9 RNP electroporation (Kim et al., 2014), lipid nanoparticle encapsulation (Hou et al., 2021), SORT ionizable lipids for targeting (Cheng et al., 2020).

How PapersFlow Helps You Research CRISPR-Cas9 Genome Editing Delivery

Discover & Search

Research Agent uses searchPapers and exaSearch to find delivery papers like 'Selective organ targeting (SORT) nanoparticles' (Cheng et al., 2020), then citationGraph reveals connections to lipid nanoparticle works (Hou et al., 2021) and findSimilarPapers uncovers RNP delivery advances (Kim et al., 2014).

Analyze & Verify

Analysis Agent applies readPaperContent to extract SORT nanoparticle protocols from Cheng et al. (2020), verifies editing efficiencies with runPythonAnalysis on dosage-response data using pandas for statistical tests, and employs verifyResponse (CoVe) with GRADE grading to confirm off-target reduction claims from Kim et al. (2014).

Synthesize & Write

Synthesis Agent detects gaps in tissue-specific delivery by flagging underexplored exosome applications (Pegtel and Gould, 2019), while Writing Agent uses latexEditText, latexSyncCitations for CRISPR protocol manuscripts, and latexCompile with exportMermaid for vector comparison diagrams.

Use Cases

"Compare editing efficiencies of LNPs vs RNPs for Cas9 delivery in hepatocytes"

Research Agent → searchPapers + findSimilarPapers → Analysis Agent → readPaperContent (Cheng/Hou/Kim papers) → runPythonAnalysis (pandas meta-analysis of efficiencies) → CSV export of stats table.

"Draft LaTeX review on SORT nanoparticles for CRISPR delivery"

Synthesis Agent → gap detection across Cheng et al. (2020) → Writing Agent → latexEditText + latexSyncCitations (10 papers) → latexCompile → PDF with cited SORT diagrams.

"Find GitHub repos with CRISPR-Cas9 delivery code from recent papers"

Research Agent → citationGraph on Kim et al. (2014) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for RNP simulation.

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'CRISPR delivery nanoparticles', structures reports with DeepScan's 7-step analysis including CoVe checkpoints on efficiency claims from Cheng et al. (2020). Theorizer generates hypotheses on exosome-CRISPR synergies by synthesizing Pegtel and Gould (2019) with Kim et al. (2014). Chain-of-Verification validates off-target data across foundational RNPs.

Frequently Asked Questions

What defines CRISPR-Cas9 genome editing delivery?

It involves vectors like nanoparticles and RNPs to deliver Cas9 and guide RNA for targeted DNA editing (Kim et al., 2014).

What are key delivery methods?

Methods include lipid nanoparticles (Hou et al., 2021), SORT nanoparticles (Cheng et al., 2020), and purified Cas9 RNPs (Kim et al., 2014).

What are major papers?

Foundational: Kim et al. (2014, 1819 citations) on RNP delivery; recent: Cheng et al. (2020, 1952 citations) on SORT nanoparticles.

What open problems exist?

Challenges include in vivo off-target minimization and tissue-specific scaling beyond hepatocytes (Cheng et al., 2020; Ramakrishna et al., 2014).

Research RNA Interference and Gene Delivery with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching CRISPR-Cas9 Genome Editing Delivery with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.